imatinib

• 伊马替尼

Imatinib Mesylate 甲磺酸伊马替尼 ; 甲磺酸伊马替尼胶囊 ; 伊马替尼 ; 甲磺酸伊玛替尼

Imatinib Mesilate甲磺酸伊马替尼

imatinib mexylate法检测甲磺酸伊马替尼

Imatinib Mesyla甲磺酸伊马替尼

imatinib sti伊马替尼

Imatinib Capsules甲磺酸伊马替尼

Imatinib Me甲磺酸伊马替尼胶囊

Imatinib Mesylat甲磺酸伊马替尼胶囊

imatinib treatment伊马替尼

• OBJECTIVE Tostudyandimprovethesynthesisofimatinibmesylate.

  目的研究和改进甲磺酸伊马替尼的合成工艺。

  www.chemyq.com

• Drugslikeimatinibandsunitinibinhibittheirprimarytargetin ananomolarconcentration.

  如imatinib和sunitinib这样的药物在纳摩尔浓度就抑制它们的主要靶点。

• Imatinibisnow thetreatmentof choice for mostnewlydiagnosedpatients.Excellentresponses, in terms ofsymptomcontrolandhaematologicalparameters, are usually obtained.

  伊马替尼是目前用来治疗新诊断患者的治疗药物，他不仅表现出了良好的治疗反应，以及症状的控制同时获得了许多较好的血液学的参数。

更多双语例句

Overriding imatinib resistance with a novel ABL kinase inhibitor
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia — NEJM
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results ...
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fr...
Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised c...
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic ...